Quintrio
Home

ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

Stereotaxis, Inc. Common Stock

STXS

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

Last trade $0.8031
Day change +$0.0004 (+0.04%)
Day range $0.803 – $0.85
Volume 477,021
Market cap $81M

Open XASE

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$80.66M
Price / earnings
—
Price / book
4.62×
Price / sales
2.68×
EV / sales
2.33×
EV / EBITDA
-3.31×

Profitability

Earnings per share
-$0.23
Return on assets
-42.44%
Return on equity
-134.97%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.42×
Quick ratio
0.95×
Cash ratio
0.39×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$15.5M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for STXS, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$7.67M$6.29M$8.64M$7.46M$8.8M$7.47M$6.34M$9.2M
Cost of revenue$3.18M$2.5M$4.32M$3.36M$4.22M$3.41M$3.12M$5.1M
Gross profit$4.49M$3.79M$4.33M$4.1M$4.58M$4.06M$3.22M$4.1M
Selling, general and administrative$6.66M$7.38M$7.27M$8.11M$7.27M$7.64M$8.05M$7.99M
Research and development$2.39M$2.4M$2.71M$2.55M$1.78M$2.35M$2.79M$2.45M
Total operating expenses$9.05M$9.78M$9.98M$10.66M$8.56M$9.99M$10.84M$10.44M
Operating income-$4.57M-$5.98M-$5.65M-$6.56M-$3.98M-$5.93M-$7.63M-$6.35M
Interest expense$0$0$118K$91K$0$0$114K$150K
Income before taxes-$4.47M-$5.86M-$5.53M-$6.46M-$3.83M-$5.82M-$7.52M-$6.19M
Income taxes$0$0$0$0$0$0$0$0
Net income-$4.47M-$5.86M-$5.53M-$6.46M-$3.83M-$5.82M-$7.52M-$6.19M
Net income attributable to common shareholders-$4.78M-$6.17M-$5.85M-$6.79M-$4.14M-$6.14M-$7.84M-$6.52M
EBITDA-$4.16M-$5.59M-$5.25M-$6.17M-$3.58M-$5.56M-$7.26M-$6.02M
Basic earnings per share-$0.05-$0.06-$0.06-$0.07-$0.05-$0.07-$0.09-$0.08
Diluted earnings per share-$0.05-$0.06-$0.06-$0.07-$0.05-$0.07-$0.09-$0.08

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity Matters

Intuitive Surgical submitted a next-generation flexible robotic endoscope to the FDA for 510(k) clearance, marking expansion into gastrointestinal care. The platform combines expertise from da Vinci surgical systems and Ion lung biopsy platform but remains in early development with no near-term revenue expected. Success will depend on regulatory approval, clinical evidence, and physician adoption.

Benzinga

Stereotaxis Eyes Billions In Market Opportunity With Robocath Takeover

Stereotaxis announced a definitive agreement to acquire Robocath, a developer of robotic technologies for interventional cardiology and neurointerventions. The acquisition is expected to contribute approximately $2 million in annual revenue in the first year and reach breakeven by year three. The deal includes a $20 million upfront payment with up to $25 million in contingent payments tied to regulatory and commercial milestones, with closing expected in mid-2026. Stereotaxis plans to pursue regulatory submissions in the US and Europe within two years and expand into electrophysiology applications.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 15, 20155-for-4forward split
Jul 11, 20121-for-10reverse split